USA, Philadelphia-based BioPhy has successfully raised $4.5 million in funding, with leading investments from Metodora Ventures, helmed by Chelsea Clinton and Caroline Kassie, along with Audere Capital, TRCM, Jeff Marrazzo, and Spark Therapeutics. The funding will be directed towards expanding the company's research and development, operational capabilities, and market presence. BioPhy is revolutionizing the drug development process through its predictive AI engine, with the aim of enhancing clinical trial outcomes, reducing failure rates, and accelerating the pace of new drug development to ultimately improve global healthcare outcomes. The company collaborates with pharmaceutical and life science organizations, including innovators like Ambrose Healthcare, to identify promising drug candidates and design effective clinical trials.